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We have studied cultured skin fibroblasts from three siblings and one unrelated individual, all of whom had fatal
mitochondrial disease manifesting soon after birth. After incubation with 1 mM glucose, these four cell strains
exhibited lactate/pyruvate ratios that were six times greater than those of controls. On further analysis, enzymatic
activities of the pyruvate dehydrogenase complex, the 2-oxoglutarate dehydrogenase complex, NADH cytochrome
c reductase, succinate dehydrogenase, and succinate cytochrome c reductase were severely deficient. In two of the
siblings the enzymatic activity of cytochrome oxidase was mildly decreased (by ∼50%). Metabolite analysis per-
formed on urine samples taken from these patients revealed high levels of glycine, leucine, valine, and isoleucine,
indicating abnormalities of both the glycine-cleavage system and branched-chain a-ketoacid dehydrogenase. In
contrast, the activities of fibroblast pyruvate carboxylase, mitochondrial aconitase, and citrate synthase were normal.
Immunoblot analysis of selected complex III subunits (core 1, cyt c1, and iron-sulfur protein) and of the pyruvate
dehydrogenase complex subunits revealed no visible changes in the levels of all examined proteins, decreasing the
possibility that an import and/or assembly factor is involved. To elucidate the underlying molecular defect, analysis
of microcell-mediated chromosome-fusion was performed between the present study’s fibroblasts (recipients) and
a panel of A9 mouse:human hybrids (donors) developed by Cuthbert et al. (1995). Complementation was observed
between the recipient cells from both families and the mouse:human hybrid clone carrying human chromosome 2.
These results indicate that the underlying defect in our patients is under the control of a nuclear gene, the locus
of which is on chromosome 2. A 5-cM interval has been identified as potentially containing the critical region for
the unknown gene. This interval maps to region 2p14-2p13.
Introduction
Inherited mitochondrial defects in which more than one
enzyme is affected with low activity are relatively com-
mon in association with mtDNA that is mutated, de-
leted, or depleted (Zeviani et al. 1989; Brown and Wal-
lace 1994; Bodnar et al. 1995; Grossman and Shou-
bridge 1996; Moraes et al. 1999). However, defects in-
volving multiple enzymopathies, which are associated
with defects in nuclear genes, are rare examples, being
abnormalities in either import proteins (Jin et al. 1996,
1999; Koehler et al. 1999) or the Lon proteases respon-
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sible for mitochondrial-protein turnover (van Dijl et al.
1998).
Fatal neonatal infantile forms of the defects associ-
ated with primary lactic acidosis have been reported,
including defects of the pyruvate dehydrogenase (PDH)
complex (PDHC) (Robinson et al. 1987a; Brown et
al. 1988; Robinson 1995; Morten et al. 1998), the
NADH–coenzyme Q reductase complex (Moreadith et
al. 1984; Hoppel et al. 1987), the cytochrome oxidase
complex (DiMauro et al. 1988; Lombes et al. 1989,
1996), and the ubiquinol cytochrome c reductase com-
plex (Kennaway 1988; Valnot et al. 1999). Here we
report two cases in which cultured skin fibroblasts
showed decreased activities of the pyruvate dehydroge-
nase complex, the 2-oxoglutarate dehydrogenase com-
plex, and succinate cytochrome c reductase. Further-
more, analysis of urine metabolites indicated possible
deficiencies of branched-chain a-ketoacid dehydroge-
nase and of the glycine-cleavage system. Here we show
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that this new syndrome is caused by a defect in a gene
located on chromosome 2p14-2p13 (84–89 cM).
Subjects, Material, and Methods
Three Siblings
Three siblings—two males and one female (cell strain
numbers 4142, 4143, and 4144)—born a few years apart
to nonconsanguineous parents after uncomplicated preg-
nancies, presented with feeding difficulty, weakness, leth-
argy, and decreasing responsiveness within a few days
after birth. Laboratory investigation showed metabolic
acidosis with elevated blood lactate levels. Assisted ven-
tilation was necessary because of respiratory failure. Urine
organic-acid analysis performed on one of the siblings
(4143) showed a highly elevated urinary lactate level, with
a secondary elevation of 2-hydroxybutyrate (5.5 mEq cre-
atinine/ml, by GC). Measurement of amino acid levels in
the blood showed glycine, leucine, isoleucine, phenylal-
anine, alanine, valine, and taurine levels to be elevated,
the most significant elevation being observed in glycine
(5.4 times the normal level). All three siblings died !1 mo
after birth. A limited autopsy was done on another sibling
(4142), and significant findings included pulmonary ox-
ygen toxicity, pneumonitis, eosinophilic infarction of the
right and left anterior papillary muscles, focal tracheal
mucosal denudation, focal intra-alveolar hemorrhage, fo-
cal renal hemorrhage, and white-matter spongiosis, all
consistent with a metabolic abnormality.
Unrelated Patient
A male infant was born by spontaneous vaginal de-
livery at 33 wk gestation, as a product of in vitro fer-
tilization, to a 30-year-old G4, P0, ectopic 3 mother (that
is, of four pregnancies, none were live births, three were
ectopic and therefore failed). The parents were first cous-
ins. During pregnancy, the mother had gestational dia-
betes and pregnancy-induced hypertension with protein-
uria. Four months after birth, the infant developed
epileptic seizures as well as elevated levels of serum gly-
cine (571 mM) and CSF glycine (28 mM). At 6 mo of
age he was developmentally delayed, and the frequency
of seizures increased. Subsequently, he developed dilated
cardiomyopathy and epileptic encephalopathy. He suf-
fered from recurrent vomiting, progressive lethargy,
tachypnea, diaphoresis, respiratory distress, and hepa-
tomegaly. At 7 mo of age he became acidotic. His initial
lactate level was 11.5 mM, but it increased to 19 mM
in the course of few weeks. His CSF glycine levels rose
to 1,039 mM, and his condition progressively deterio-
rated. He died at 11 mo of age.
Cell Lines
The cell lines used in this study were obtained by skin
biopsy of the forearm of patients, after informed consent
was obtained. Primary fibroblast lines were established
from the four patients (4142, 4143, 4144, and 11571)
with compound mitochondrial-enzyme deficiency, all of
whom exhibited the same biochemical phenotype. Fi-
broblasts were grown in Eagle’s minimal essential me-
dium (a-MEM) and 10% fetal calf serum, supplemented
with glucose to a concentration of 10.5 mM. Measure-
ments of the lactate-to-pyruvate (L/P) ratio in confluent
fibroblast cultures were performed as described else-
where (Robinson et al. 1985). The primary fibroblast
cell lines were transduced with a retroviral vector ex-
pressing the E6E7 region of type 16 human papilloma
virus, to extend their life span (Compton 1993), and
were grown in high-glucose Dulbecco’s minimal essen-
tial medium (DMEM) supplemented with 20% fetal bo-
vine serum.
Microcell-Mediated Chromosome Transfer
A panel of human:mouse monochromosomal hybrids
(Cuthbert et al. 1995) was used as the source of normal
human donor chromosomes. All 22 autosomes and the
X chromosome were serially transferred into one of the
patient cell lines by microcell-mediated chromosome
transfer (Fournier 1981). In brief, donor cells were
plated in a-MEM containing 10% fetal bovine serum
and hygromycin B (400 U/ml; ICN), 3 d before fusion.
The medium was then changed to DMEM plus 20%
fetal bovine serum, and the cells were exposed to col-
chicine (0.06 mg/ml) for 48 h to induce micronucleation.
The cells were then collected by trypsinization and were
plated on plastic “bullets” (custom made from tissue-
culture plates, to fit into 50-ml centrifuge tubes) coated
with cross-linked concanavalin A (Sigma). Microcells
were prepared by centrifugation at 34C–37C and
15,000 g (SS34 rotor) in media containing cytochalasin
B (10 mg/ml; Sigma), were filtered through 8-mm and 5-
mm filters, were pelleted at 3,000 g on a benchtop cen-
trifuge, and were resuspended in serum-free medium.
The microcell suspension and phytohemagglutinin were
added to the plate containing the recipient cells (100 mg/
ml) and incubated for 20–30 min. Microcells were fused
with 45% polyethylene glycol plus 10% dimethyl sulf-
oxide for 60 s, washed with serum-free medium, and
incubated in a-MEM plus 20% fetal bovine serum. After
48–72 h, fused cells were selected in hygromycin B (100
U/ml). Colonies were picked, expanded, and analyzed
3–4 wk later.
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Enzymology and Spectrophotometric and
Immunological Analysis
Activity of the PDH complex in both the native (un-
stimulated) and the dichloroacetate-activated state was
determined in fibroblast extracts by the method of Sheu
et al. (1981). Activity of the 2-oxoglutarate complex was
determined in fibroblast extracts by the method of Hy-
land and Leonard (1983). Activity of the NADH cyto-
chrome c reductase was assayed in 0.1 M potassium
phosphate (KPi) buffer (pH 7.0) containing 94 mM cy-
tochrome c and 1mM azide. To start the reaction, 20
mM NADH was added, and reduction of cytochrome c
was monitored at 550 nm. Cytochrome oxidase activity
was assayed in 0.1 M KPi buffer (pH 7.0). Cytochrome
c was reduced with 3.2 mM ascorbate, followed by di-
alysis against 0.1 M KPi for 2 d, during which the buffer
was changed twice. Reduced cytochrome c (94 mM) was
added to start the reaction, and oxidation of cytochrome
c was monitored at 550 nm. Citrate synthase assay was
performed as described by Robinson et al. (1987b). Suc-
cinate dehydrogenase activity was determined in mito-
chondria purified from skin fibroblasts by the method
of Hatefi and Stiggall (1978). Succinate cytochrome c
reductase activity was determined in fibroblast extracts
by the method of Yu and Yu (1982). Aconitase activity
was determined in mitochondria purified from skin fi-
broblasts by the method of Racker (1950). Activity of
the bc1 complex was determined according to the
method described by Darley-Usmar et al. (1987). West-
ern blotting was performed on mitochondrial extracts
prepared by the method of Pitka¨nen et al. (1996), using
polyclonal antibodies against (a) porcine-heart PDH-
complex raised in rabbit (Ekong 1982) and (b) holo bc1
and iron-sulfur protein (ISP)–bc1 bovine heart-and-liver
complex raised in rabbit (Vazquez-Acevedo et al. 1993).
Preparation of Human Liver Mitochondria
Mitochondria were isolated from frozen post-mortem
human livers by a method that is a combination of those
described by Pitka¨nen et al. (1996) and Craig and Hood
(1997). Tissues were finely minced and then were gently
homogenized in buffer (50 mM HEPES, pH 7.4, 70 mM
sucrose, 220 mM mannitol, 1 mM EGTA and 2 mg fatty
acid–free BSA/ml) (Sigma-Aldrich). After homogeniza-
tion, the mixture was centrifuged at 3,000 g for 10 min.
The supernatant was then centrifuged at 15,000 g for
10 min. The pellet was gently solubilized in homoge-
nization buffer, and the centrifugation steps were re-
peated. The pellet was resolubilized and recentrifuged at
15,000 g for a final time. Then the mitochondrial pellet
was resuspended in buffer (0.34 M sucrose, 100 mM
KCl, 10 mM Tris-Cl, and 1 mM EDTA) at a concen-
tration of 1 mg/ml.
Free Radical–Production Assay
Superoxide production was determined using the
chemiluminescent dye lucigenin (10,10-dimethyl-9,9-
biacridinium dinitrate; Sigma) (Pitka¨nen and Robinson
1996). The concentration of the working solution of
lucigenin was 4.3 mM. The measurements were per-
formed in buffer containing 70 mM sucrose, 220 mM
mannitol, 2.5 mM KPi (pH 7.5), 2.5 mM MgCl2, 0.5
mM EDTA, and 0.1% BSA. Lucigenin was added to the
buffer immediately before measurements were taken. All
measurements were made at room temperature, with a
Lumat luminometer (model 9507; Berthold). The signal
from the dye was integrated over a period of 30 s after
the addition of substrate (2 mM succinate), and the
background signal during this same period was sub-
tracted from the sample signal. Mitochondria were
preincubated, with or without inhibitors, in the mea-
surement buffer for 1 min prior to addition of substrate.
The substrate was added using the automatic-injection
system of the Lumat 9507, after determination of the
background signal during a 15-s period. Measurements
were carried out in the presence or absence of either
antimycin A (final concentration 20 mg/ml), myxothiazol
(final concentration 10 mM) (Sigma-Aldrich), or stig-
matellin (final concentration 20 mM) (Fluka Biochemi-
cals). These inhibitor concentrations were shown to fully
inhibit enzyme activity (Raha et al. 2000). Ten micro-
grams of mitochondrial proteins per sample was used
for luminometric monitoring.
Deletion and Exclusion Mapping
Oligonucleotide primers for polymorphic microsat-
ellite markers on chromosome 2 were obtained (Re-
search Genetics, Huntsville, Alabama and ACGT, To-
ronto). Deletion mapping was done on DNA isolated
from hygromycin B–resistant clones obtained, after mi-
crocell fusion, from the A9-2 monochromosomal hybrid
line, by a Pure Gene kit (Gentra Systems, Minneapolis).
Exclusion mapping was carried out on the three affected
siblings as well as on the family of the unrelated indi-
vidual. This family included the affected individual, his
brother, and both parents. Genomic DNA for this ex-
periment was isolated from primary skin fibroblasts,
with a total-DNA–isolation kit (Qiagen). PCR was per-
formed using the Research Genetics protocol, AmpliTaq
Gold (PE Biosystems), and g35S-dATP. PCR products
were run on 6% sequencing gels exposed overnight, with
BioMax film (Kodak), and developed. PCR was also
performed, as above, in the absence of g35S-dATP. Prod-
ucts were run on Supergel 250TM (Helixx); gels were
stained with Sybr Green (Helixx, Toronto) for 20 min,
and DNA bands were visualized by UV illumination.
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Table 1
Various Mitochondrial Enzyme Activities of Patients Suffering from the Multiple Disorder
ENZYMEa
MEAN  SEM ACTIVITYb [NO. OF DETERMINATIONS] IN
(nmol/min/mg)
Control Sibling 1 (4142) Sibling 2 (4143) Sibling 3 (4144)
Unrelated Patient
(11571)
PDHC (active) .98.14 [9] .16.04 [6] .22.05 [10] .05.02 [9] .21.04 [4]
PDHC (DCA activated) 1.16.16 [9] .13.03 [6] .25.06 [10] .04.02 [8] .36.06 [4]
PDH E1 1.41.21 [5] .48 [1] .63 [1] .36.07 [5] N/A
PDH E2 10.683.89 [2] 12.04 [1] 12.19 [1] 8.861.92 [2] N/A
PDH E3 7.20.53 [2] 9.26 [1] 7.34 [1] 7.21.60 [2] N/A
OGDHC 1.48.33 [4] 0.20.06 [2] .37.05 [2] .12.05 [2] 0.42.06 [2]
NCR (I  III) 6.38.22 [5] 1.95.38 [4] 1.02.25 [4] 1.27.47 [3] 1.98.53 [3]
COX 5.18.69 [4] 5.07.28 [3] 2.23.46 [4] 2.70.56 [3] 4.95.50 [4]
L/P ratio 27.13.5 [6] 105.528.4 [4] 157.020.7 [8] 187.715.1 [4] 101.26.5 [4]
Pyruvate carboxylase 1.38.29 [3] 2.33 [1] .42 [1] 1.46 [1] 1.17 [1]
Citrate synthase 39.678.34 [2] N/A 35.347.30 [2] 32.025.76 [2] 42.866.30 [2]
SDH 16.0  2.4 [4] N/A 7.0 .2 [2] N/A 6.9  .2 [2]
Mitochondrial aconitase 4.0  .6 [2] N/A 3.5  .6 [2] N/A 3.2 .5 [2]
bc1 complex (complex III)
c 6.9  1.5 [4] 4.5  .8 [2] 3.8  .7 [2] N/A 3.9  .9 [3]
SCR 5.941.01 [2] N/A 1.41.33 [2] 1.57.36 [2] 2.17.71 [2]
a NCR (complexes IIII)p NADH cytochrome c reductase (complexes I  III); SDH p succinate dehydrogenase (complex II);
SCR p succinate cytochrome c reductase (complexes II  III).
b Determined in cultured skin fibroblasts from each patient and a group of controls. Individual determinations were made on
separate cultures on different days, and multiple control cell lines were used.
c Data standardized to levels of citrate synthase.
Results
Skin fibroblast cultures established from three siblings
and one unrelated patient showed a four- to sevenfold
elevation in the L/P ratio formed on incubation with 1
mM glucose for 1 h (Robinson et al. 1987a) (table 1).
A very low activity of the pyruvate dehydrogenase com-
plex was also recorded, with values in the dichloroac-
etate-activated state reaching, at most, 25% of the con-
trol value. Furthermore, breakdown of the activities of
individual PDH-complex components revealed a de-
creased activity of the first subcomplex, pyruvate de-
hydrogenase (designated “E1”), whereas the activities of
the remaining components, dihydrolipoamide transa-
cetylase (designated “E2”) and dihydrolipoamide dehy-
drogenase (designated “E3”), were normal. Activities of
the NADH cytochrome c reductase (complexes I  III),
succinate cytochrome c reductase (complexes II  III),
succinate dehydrogenase (complex II) bc1 complex (com-
plex III), and the 2-oxoglutarate dehydrogenase complex
were also decreased, reaching, at most, 30%, 35%,
45%, 60%, and 28%, respectively, of control values.
The activity of cytochrome c oxidase (COX) was de-
creased to ∼50% of control values in two of the siblings
(4143 and 4144). In contrast, activity values for pyru-
vate carboxylase, mitochondrial aconitase, and citrate
synthase were normal. The above-described phenotype
was observed in both primary and transformed cells
(data not shown). Transformation did not alter enzy-
matic activities of the assayed complexes. Urine organic-
acid analysis performed on one of the siblings (4143)
showed a highly elevated urinary lactate level with a
secondary elevation of 2-hyroxybutyrate (5.548 mEq/ml
creatinine by GC). In all four patients, amino acid levels
in the blood showed glycine, leucine, isoleucine, phe-
nylalanine, alanine, valine, and taurine at above-normal
levels, with the most significant abnormality being a five-
fold elevation in glycine.
To determine the chromosomal location of the gene
defect in these patients, we rescued this phenotype by
functional complementation with a normal human
chromosome transferred into deficient cells by micro-
cell-mediated chromosome transfer. A panel of stable
human:mouse hybrid cell lines containing human chro-
mosomes tagged with a selectable marker (HyTK) was
used as a source of donor human chromosomes (Cuth-
bert et al. 1995). Autosomes (with the exception of
chromosomes 1, 9, 13, 15, 17, and 21) and the X chro-
mosome were transferred, one at a time, into a patient
fibroblast line (4143, one of the three siblings), and the
cells were selected in hygromycin B. Three to four weeks
postfusion, surviving colonies were picked, and PDH-
complex activity was measured in pooled colonies ob-
tained for each individual chromosome transfer. Trans-
fer of chromosome 2 (A9.2 human:mouse hybrid cell
line) restored PDH complex activity to control levels
(table 2). This restoration was not observed with either
any other autosome or the X chromosome (table 2).
Transfer of chromosome 2 also restored the activity of
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Table 2
Functional Complementation Analysis, with a Panel of Human
Chromosomes, of Skin Fibroblasts from a Patient Suffering from
Multiple Mitochondrial Enzyme Disorder
CHROMOSOME
OR SOURCE
MEAN  SEM ACTIVITYa [NO. OF
DETERMINATIONS] OF
(nmol/min/mg cell protein)
NADH
Cytochrome
c Reductase
(Complexes I
& III)
PDH Complex
Native DCA Activated
1 NA NA NA
2 5.98.34 [4] 1.12.09 [9] 1.5.145 [9]
3 … .21.04 [2] .24.06 [2]
4 1.99.71 [2] .23.07 [3] .23.04 [3]
5 1.87.45 [2] .25.06 [2] .19.04 [2]
6 … .19.02 [2] .29.05 [2]
7 … .22.05 [3] .20 .03 [3]
8 2.08.43 [2] .30.06 [2] .31.04 [2]
9 NA NA NA
10 … .14.07 [2] .17.05 [2]
11 … .028.06 [2] .25.04 [2]
12 … .18.03 [2] .23.05 [2]
13 NA NA NA
14 2.24.39 [2] .26.06 [3] .21.03 [3]
15 NA NA NA
16 1.99.22 [2] .29.08 [3] .28.07 [3]
17 NA NA NA
18 … .28.04 [2] .20.04 [2]
19 2.13.45 [2] .23.06 [2] .25.05 [2]
20 … .26.05 [2] .30.04 [2]
21 NA NA NA
22 2.56.63 [2] .22.05 [2] .27.04 [2]
X … .34.07 [2] .29.03 [2]
Patient 4143 1.02.25 [4] .22.05 [10] .24.05 [10]
Control 6.56.58 [5] .98.08 [9] 1.21.14 [9]
a Measured after microcell-mediated transfer of single HyTK-
tagged normal human chromosomes into fibroblasts from patient
4143 (one of the three siblings). For multiple pooled clones recovered
after selection in hygromycin B. NA p transfer of chromosome not
performed. An ellipsis (…) denotes that activity was not measured.
the 2-oxoglutarate dehydrogenase complex and the
NADH cytochrome c reductase in that cell line (4143).
To confirm a common genotype in the selected pa-
tients, we transferred chromosome 2 into skin fibro-
blasts obtained from another affected sibling (4142) and
from the unrelated patient (11571). Additional clones
were isolated from the latter patient. As had been seen
in the previous results, this chromosome restored activ-
ities of all assayed enzyme complexes (table 3).
We also tested PDH-complex activities in individual
clones obtained from patients 4143 and 11571. Enzyme
activity was restored in 23/25 independent clones de-
rived from patient 4143 and in 30/36 clones in cells
derived from patient 11571 (data not shown).
To narrow the potential locus region on chromosome
2, we genotyped three affected siblings, as well as the
unrelated patient, his parents, and his unaffected brother
with a set of chromosome-2 microsatellite markers. At
the locus of the gene defect, affected family members, in
theory, should share common alleles while being discor-
dant with unaffected family members. This analysis re-
sulted in isolation of two regions of interest: one on the
p arm and the other on the q arm of chromosome 2
(table 4). The region on the p arm extended between
markers D2S1337 and D2S1790 (∼24 cM), and the re-
gion on the q arm extended between markers D2S434
and D2S407 (∼18 cM). During the course of this exper-
iment we had to exclude the family of the unrelated pa-
tient because the extremely high degree of consanguinity
(the parents were first cousins) rendered the data non-
informative.
Chromosomes incorporated into the genome of re-
cipient cells by microcell transfer often undergo dele-
tions and rearrangements (Leach et al. 1989; Newbold
and Cuthbert 1996). To eliminate one of the two can-
didate regions obtained by exclusion mapping, as well
as to obtain a narrower chromosomal interval contain-
ing the gene of interest, we used polymorphic micro-
satellite markers from chromosome 2. We mapped the
regions that were incorporated into the genomes of
complemented and noncomplemented clones isolated
from patients 4143 and 11571 after hygromycin B se-
lection. In functionally complemented clones, markers
that are missing from the exogenous chromosome could
be excluded from the region of interest; similarly, in
noncomplemented clones, informative markers that are
present could be excluded as well. Analysis of 13 com-
plemented clones and 1 noncomplemented clone from
patient 4143, and of 10 complemented and 6 noncom-
plemented clones from patient 11571, allowed the map-
ping of the gene defect to the region between markers
A053XF9 and GATA-P132045 (∼5 cM) (table 5). This
analysis excluded the region, on the q arm of chro-
mosome 2, obtained by marker analysis in the three
siblings. Cumulative data for both exclusion and dele-
tion mapping are shown in figure 1. During the exclu-
sion-mapping experiment it became apparent that nei-
ther the immortalization of the primary cells nor the
chromosome-transfer procedure resulted in the loss of
cellular heterozygosity, owing to the fact that, with in-
formative sequence-tagged site (STS) markers, endoge-
nous and exogenous alleles could be easily identified.
To determine whether the genetic defect shared by the
affected individuals had any impact on the amount of
protein expressed for the deficient complexes, immu-
noblotting was performed using antibodies directed
against the total PDH complex, the holo bc1 complex,
and the bc1 complex ISP. These immunoblots show that
four components of the PDH complex and three com-
ponents of the bc1 complex are expressed at levels com-
parable to those in control samples (fig. 2). This indi-
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Table 3
Functional Complementation Analysis of Selected Enzyme Complexes (the bc1, the PDHC,
and the 2-OGDHC), Pre- and Post-Chromosome 2 Transfer
CELL LINE
MEAN  SEM ACTIVITY [NO. OF DETERMINATIONS] OF
(nmol/min/mg cell protein)
NADH Cytochrome
c Reductase
PDH Complex
2-OGDHCNative DCA Activated
4143 1.02.25 [4] .22.05 [10] .24.05 [10] .37.05 [2]
4143 x chr 2 5.98.33 [4] 1.12.09 [9] 1.50.14 [9] 1.04.10 [2]
4142 1.95.38 [4] .16.04 [3] .24.04 [3] .11.09 [2]
4142 x chr 2 6.621.05 [2] .91.09 [4] 1.33.18 [4] 1.13.16 [2]
11571 2.28.53 [3] .21.03 [4] .36.06 [4] .42.06 [2]
11571 x chr 2 4.56.58 [3] 1.11.09 [6] 1.52.15 [6] 1.29.13 [2]
Control 6.56.58 [5] .98.08 [9] 1.21.14 [9] 1.34.13 [4]
cates that the disorder does not affect the import,
assembly, or stability of the investigated complexes,
since all protein levels investigated are quite normal de-
spite the proven lack of activities in the enzyme com-
plexes.
Superoxide can be generated from two potential sites
within the bc1 complex (Raha et al. 2000). Inhibition
with antimycin A prevents transfer of electrons from
cytochrome b to Qi, thereby increasing the concentra-
tion of Qo semiquinone. This increase in the Qo semi-
quinone species results in an increase in the free-radical
species, since superoxide is formed by donation of an
electron from Qo to molecular oxygen (Raha et al.
2000). The antimycin A–dependent increase in produc-
tion of superoxide was observed for the control human
liver mitochondria (table 6). However, liver mitochon-
dria obtained from the autopsied liver of one of the
siblings failed to produce any significant increase in free-
radical production after addition of antimycin A. More-
over, a statistically significant decrease in free-radical
production was observed (table 6). Addition of either
myxothiazol (100 mM) or stigmatellin (20 mM) to the
liver mitochondria from either the patient or the control
produced only a marginal (i.e., statistically nonsignifi-
cant) increase in the production of superoxides, above
basal levels.
Discussion
Investigations of the cultured skin fibroblasts derived
from the three siblings (4142, 4143, and 4144) and from
the unrelated patient (11571) showed an increased L/P
ratio in the cells, typical of a severe respiratory-chain
problem (Robinson et al. 1985, 1990). Deficient activ-
ities of NADH cytochrome c reductase, the pyruvate
dehydrogenase complex, the 2-oxoglutarate dehydrog-
enase complex, and succinate cytochrome c reductase
suggested the presence of a defect that was decreasing
the activity of several mitochondrial enzymes. This was
further confirmed by metabolite analysis of the blood,
pointing to a deficiency of both the branched-chain a-
keto acid dehydrogenase complex and the glycine-cleav-
age system. However, the activities of pyruvate carbox-
ylase, mitochondrial aconitase, lipoamide dehydro-
genase (i.e., E3), and citrate synthase were normal. Im-
munoblot analysis performed on mitochondrial extracts
derived from the four patient cells (fig. 2) showed that
the pattern of the selected subunits (the PDH complex
and the bc1 complex) was similar to that of the control
cell line. This observation suggests that the examined
polypeptides are correctly imported into and/or folded
within the mitochondria and are assembled into com-
plexes. Previous studies have indicated that patients with
a defect in mitochondrial import machinery present with
a lack of immunodetectable proteins within the organelle
(Jin et al. 1999). Similarly, deficiencies in factors required
for assembly of multisubunit complexes produce, at best,
only partially assembled complexes (Brasseur et al.
1997; Petruzzella et al. 1998). This would indicate that
the above-described genetic defect occurs at the post-
translational—and, probably, postassembly—level.
In both families there was no previous history of
individuals on the maternal side who had symptoms
associated with mitochondrial myopathy. Although
mtDNA was not analyzed for pathogenic mutations, the
fact that the majority of the affected enzyme complexes
have no mitochondrially encoded components makes mi-
tochondrial aberrations an unlikely cause.
In trying to pinpoint a genetic defect that would
explain all of the above-described results, we decided
to conduct functional complementation analysis using
microcell-mediated chromosome transfer. Our results
clearly show that introduction of a normal chromosome
2 into the three cell lines with multiple mitochondrial
enzyme deficiency can revert their phenotype and re-
store enzyme activities. Evidence that phenotypic
changes were not the mere consequence of manipula-
tions associated with the chromosome-transfer proto-
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Table 4
Results of Exclusion-Mapping Performed on Three Siblings
POSITION
(cM) MARKER
ALLELE SIZE INa
(base pairs)
Sibling 1 Sibling 2 Sibling 3 Control
15 D2S1780 224/232 220/? 224 …
24 D2S423 177/183 174/183 177 177/180
29 D2S1400 110 110/114 110/114 114
42 D2S1360 135/143 135/143 135/159 151/155
41 D2S405 249 249 241/249 249
63 D2S1348 174/180 159/180 174/180 171
70 D2S1356 ? 202/208 202/226 202/?
81 D2S1337 145/147 145/147 139/145 143/147
90 D2S441 154 154 154 162/174
95 D2S1394 168 168 168 160/172
100 D2S1777 201 201 201 198/202
107 GATA26G08 137/145 137/145 137/145 …
108 D2S1790 284/328 284/328 284/328 …
120 D2S2972 227/231 227/231 231/239 227/231
125 D2S1784 205/209 201/205 205/209 209
130 D2S410 165/173 163/165? 163/173 165/169
138 D2S1328 140/152 140/152 140 …
146 D2S112 135/137 137/142 133/135 137
150 D2S442 197/201 201/205 197/201 197/205
152 D2S1326 242/254 238/246 242/254 258/266
? D2S1353 144/147 144 … 144
180 D2S1776 297 297 285/297 297
187 D2S2981 233/249 233/249 241/249 249
189 D2S300 138/142 138 142 142
191 D2S1391 115/123 115/123 123 127/131
201 D2S2735 248/252 248/252 236/244 240/244
212 D2S1369 264/268 264/268 256/268 256
222 D2S434 266/270 270/274 … 266/270
233 D2S1363 186/190 186/190 178/186 182/190
236 GATAE08 191 191 191 …
244 D2S427 254 254 254 214/254
253 D2S407 195 195 195 195
267 D2S2285 253/259 253/259 253/259 …
NOTE.—A set of chromosome 2 markers was used for microsatellite
analysis by PCR to isolate regions where the affected family members
share common alleles (boxed areas).
a Single values indicate homozygosity for that individual. The con-
trol individual is not related to the affected siblings. An ellipsis (…)
is used when definitive designation of alleles was not possible.
cols but were truly controlled by chromosome 2–specific
DNA sequences comes from three observations. First,
similar changes were not seen when chromosomes other
than chromosome 2 were transferred into the same re-
cipient cells. Second, genotype analysis of chromosome
2 markers for the three siblings gave two regions, one
at 2p and one at 2q, in which all three siblings had
common alleles. Third, only a small (5 cM) portion of
the exogenous chromosome 2p in the hybrid cell line
resulted in restoration of affected enzyme activities, fur-
ther attesting to the association between these pheno-
typic properties and specific DNA sequences. This re-
gion, when absent in hybrid cell lines after chromosome
2 transfer, produced clones that still exhibited the mu-
tant phenotype (one clone from patient 4143 and six
clones from patient 11571; see the Results section).
Our ultimate goal in this study was to better define
the chromosomal region(s) associated with the disorder
that causes multiple mitochondrial enzyme malfunc-
tions, in order to facilitate the eventual isolation of the
specific gene(s) controlling this disorder. This was
achieved with subclones of chromosome 2 hybrids that
did not regain their affected enzyme activities. Exami-
nation of the integrity of the exogenous chromosome 2
in these clones showed that portions of the chromosome
had been lost in each case. Similarly, examination of
the integrity of the exogenous chromosome 2 clones that
reverted to the mutant phenotype showed that, in these
revertants, portions of it had been lost in each case. The
smallest deletion that could be defined by this approach
extended from A053XF9 to GATA-P132045 (table 5
and fig. 1). Most of the known polymorphisms within
this region were noninformative, because the corre-
sponding alleles on the exogenous chromosome were
indistinguishable from alleles on the endogenous copies.
This complicated attempts at further narrowing this
candidate region.
Results from the measurement of bc1 complex (i.e.,
complex III) superoxide production (a) indicate that
there is only a residual transfer of electrons from ubi-
quinone to the iron-sulfur center in the deficient cell line
and (b) confirm a deficiency in the overall functioning
of that complex. This reasoning is based on the obser-
vation that inhibition of electron flow between coen-
zyme b562 and Qi, by antimycin, failed to produce any
significant increase in reactive-species production (Raha
et al. 2000). How can these observations be compatible
with the Western-blot data suggesting that the ISP is
fully assembled into the bc1 complex? Kapazoglou et al.
(2000) showed that, in a triple-substitution mutant,
C107S/H109R/C112S, the replacement of conserved
residues involved in the ligation of the [2Fe-2S] center
of the Rieske protein allowed the latter, in isolated chlo-
roplasts, to assemble into the cytochrome bf complex,
which nonetheless was an inactive complex. The cyto-
chrome bf complex and the mitochondrial bc1 complex
share a high degree of topological and functional sim-
ilarity, especially with regard to the Rieske protein (So-
riano et al. 1999). Therefore, a lack of incorporation
of this [2Fe-2S] center may be a reasonable explanation
for the activity loss in these patients.
In the attempt to determine the nature of the genetic
defect underlying the above-described disorder, the
identification of a common factor or process involved
in all the affected enzyme complexes is all-important.
An interesting biochemical characteristic of this disorder
is the fact that, although the activities of the isolated
respiratory enzymes II and III retain quite high intrinsic
Table 5
A Deletion Map for Two Patients with Novel Mitochondrial Syndrome
POSITION
(cM) MARKER
RESULTS OF MICROSATELLITE PCRa
Noncomplementing Clones Complementing Clones
Cell
Line
4143 Cell Line 11571 Cell Line 4143 Cell Line 11571
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
84 A053XF9 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI      ?    
86 A346YB5 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI     ?     
88 309VC1 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI          
89 GATA-P32045 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI      ?    
90 GATA-P18038               ?               
90 D2S441                       ?  ? ?    
92 D2S1355 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI      ?    
D2S303  NI NI NI NI NI NI              NI NI NI NI NI NI NI NI NI NI
95 D2S1394  NI NI NI NI NI NI       ? ?  ?    NI NI NI NI NI NI NI NI NI NI
D2S1398           ?            ?       
98 D2S1351 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI      ?   ? 
100 GATA-P18021  NI NI NI NI NI NI        ?      NI NI NI NI NI NI NI NI NI NI
D2S116                          ?    
107 GATA-P9284                          ?    
108 D2S1790                 ?         ?    
138 D2S1328       
148 D2S1334       
180 D2S1776       
191 D2S1391       
233 D2S1363                              
236 D2S439 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI          
244 D2S427 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI    ?      
253 D2S336             ?   ?              
253 D2S407 NI       NI NI NI NI NI NI NI NI NI NI NI NI NI   ?       
a Plus () signs and minus () signs indicate the presence or absence, respectively, of STS markers. NI p marker not informative. ?- unable to clearly include or exclude marker. Recipient
patient-derived cell lines (either 4143 or 11571) are indicated above each set of results. Only noncomplemented clones were analyzed using markers D2S1328, D2S1334, D2S1779, and
D2S1391. Markers D2S2110, D2S1777, D2S428, D2S2213, and MR14788 were not informative for all analyzed clones and therefore are not included. The candidate region is boxed.
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Figure 1 Ideogram of human chromosome 2 showing results of
exclusion and deletion mapping for the mitochondrial multienzyme-
deficiency phenotype. Microsatellite markers that were used in the
analysis are indicated. The thicker vertical lines to the right of the
markers indicate regions that were obtained by either deletion or ex-
clusion mapping.
Figure 2 Western blot analysis of endogenous expression of py-
ruvate dehydrogenase complex (A), core I and cytochrome c of the
bc1 complex (B), and bc1 complex ISP (C). Aliquots (60 mg) of total
protein from mitochondria-rich fractions were separated on 12.5%
SDS/polyacrylamide gel and then were transferred to nitrocellulose.
The filter was probed with antibody against affinity-purified pig heart
PDH complex raised in rabbit (A), or with antibody against either
holo bc1 complex, or bc1-ISP raised in rabbit (B and C). The mito-
chondrial extracts present on the gels are, from left to right, control
cultured-skin fibroblasts (lane 1), skin fibroblasts from two affected
siblings (4143 and 4144) (lanes 2 and 3), and fibroblasts from the
unrelated patient (11571) (lane 4). In C the sample for the unrelated
patient is not present.
values (45%–60%), the combined activities of com-
plexes IIII and complexes IIIII are more dramatically
suppressed (table 2). These results could suggest a defect
in the mitochondrial coenzyme Q content and/or func-
tion, since both system IIII and system IIIII require
it as an electron carrier. Similar biochemical findings
were reported, in a case of intrinsic muscle coenzyme
Q deficiency, by Boitier et al. (1998). However, this
hypothesis cannot explain the observed deficiencies of
either the mitochondrial dehydrogenases (PDHC, 2-
oxoglutarate dehydrogenase complex [OGDHC], and
branched chain a-ketoacid dehydrogenase complex
[BCKDHC]) or the glycine-cleavage system.
A more plausible explanation is provided by the pos-
sibility that the unknown factor is somehow involved
in the metabolism of sulfur in the mitochondria and/or
the supply of sulfur to the affected complexes. Sulfur is
an essential part of lipoic acid, which is a cofactor
shared by the PDH complex, the 2-oxoglutarate de-
hydrogenase complex, the branched-chain a-keto acid
dehydrogenase complex, and the glycine-cleavage sys-
tem. Sulfur is also a part of respiratory complexes II
and III, in the form of the iron-sulfur centers, and cys-
teine desulfurase and sulfur transferase are required for
assembly. In contrast, assembled sulfur-containing ac-
tive centers are not a part of either the pyruvate car-
boxylase complex or the citrate synthase complex.
Given the second hypothesis, how can we explain the
fact that mitochondrial aconitase—an iron-sulfur cen-
ter–containing enzyme—is not affected? In the past, it
has been reported that, in respiratory-chain abnormal-
ities involving iron-sulfur clusters, mitochondrial acon-
itase activity was also depressed (Hall et al. 1993; Rotig
et al. 1997). However, no link was reported between
these disorders and the activities of mitochondrial de-
hydrogenases. Furthermore, in the case of Friedreich
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Table 6
Effect of Inhibitor-Dependent Superoxide Production in
Control and Multi-Complex Deficient Liver Mitochondria
INHIBITOR
MEAN  SEM SUPEROXIDE
FORMATIONa [NO. OF
DETERMINATIONS]
(rel V/min)
Control Sibling 1
No inhibitor 343  49 [4] 349  24 [4]
Antimycin A (20 mg/ml) 1,402  123 [4] 107  46 [8]
Stigmatellin (20 mM) 380  33 [4] 408  61 [4]
Myxothiazol (10 mM) 413  67 [4] 431  71 [4]
a Monitored using lucigenin luminescence after addition of
succinate (5 mM) to mitochondrial suspension in the presence
or absence of either antimycin A (see Subjects, Materials, and
Methods section), stigmatellin, or myxothiazol. Values were
standardized to the activity of citrate synthase, a mitochondrial
matrix marker.
ataxia, in which mutated frataxin triggers aconitase and
mitochondrial iron-sulfur respiratory-enzyme deficien-
cy, the defect stems from abnormal iron homeostasis
rather than from sulfur homeostasis. Therefore, it is
very possible that the mechanisms of sulfur insertion
into iron-sulfur centers for respiratory-chain complexes
and lipoic acid are different from the mechanisms re-
quired for aconitase.
The nearly completed Human Genome Project should
provide sequence information about the isolated chro-
mosome 2 interval where the locus for the unknown
gene is most likely located. At the time of submission,
extensive searches throughout this region, which con-
tains30 predicted genes, have yielded no obvious can-
didates. Future work will determine whether the gene
product involved proves to have either a sulfur trans-
ferase activity or a cysteine desulfurase activity. Ex-
amination of data from the Human Genome Project that
are particular to this locus reveals that it is a relatively
gene-rich region with a mix of well-characterized genes,
such as malate dehydrogenase, and other less–well-de-
fined genes. After extensive analysis, we could find, in
the region of chromosome 2p14-2p13, no indication of
either sulfur transferase genes or genes involved in ubi-
quinone synthesis.
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